Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Shots:
- The approval is based on P-III E1912 study assessing Imbruvica + rituximab (IR) followed by ibrutinib until disease progression or unacceptable toxicity- or six cycles of FCR in 529 previously untreated CLL patients aged ≤70 yrs.
- Results: @median follow-up of 37 mos. IR treated patients lived longer without disease progression with a PFS (88 %)- compared to 75 % for FCR treated patients. The study also showed an OS advantage for the IR regimen
- Ibrutinib (oral- qd) is a first-in-class BTK inhibitor that blocks the BTK protein and helps abnormal B cells movement out of their nourishing environments in the lymph nodes- bone marrow- and other organs. Ibrutinib is approved for CLL- MCL- and WM in Europe and in 99+ countries for at least one indication
Ref: PRNewswire | Image: Janssen
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com